#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 13

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Endometrial cancer

Not yet recruiting

Registered drugNo placebo

Study Comparing Chemotherapy Alone to Dostarlimab, Paclitaxel, and Carboplatin for Patients with Advanced or Metastatic Endometrial Cancer

Registered drugNo placebo

France

Participants:18–64 years
Substances:Carboplatin

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Registered drugNo placebo

Study of Dasatinib for Patients with Acute Myeloid Leukemia Not Responding to Venetoclax-Azacitidine Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dasatinib

Contact Research Centre

Breast cancer

Not yet recruiting

Registered drugNo placebo

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Triple negative breast cancer

Not yet recruiting

InvestigationalNo placebo

Study on Early Detection of Triple-Negative Breast Cancer Relapse Using [68Ga]Ga-FAPI-46 for Patients at High Risk

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Gastric cancer+1

Not recruiting

Registered drug

Study on Durvalumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Hormone receptor positive breast cancer+1

Not recruiting

Registered drugNo placebo

Study Comparing DB-1303 and Chemotherapy for Patients with HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Arteriosclerosis

Not recruiting

Registered drug

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Inclisiran

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

InvestigationalNo placebo

Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:PUCOTENLIMAB

Contact Research Centre

Non-small cell lung cancer metastatic

Not recruiting

Registered drugNo placebo

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acasunlimab

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Non-small cell lung cancer stage IV

Not recruiting

Registered drugNo placebo

Study on Continuing Nivolumab and Ipilimumab Treatment vs. Observation in Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ipilimumab

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.